Clinical trial
A Phase 1B Open-label/Phase 2 Double-blind Placebo- Controlled Study for Pharmacodynamic (PD) Activity, Pharmacokinetics (PK), Safety, and Tolerability of KAN-101 In Patients With Celiac Disease (CeD)
NCT05574010 is registered in ClinicalTrials.gov with Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1B Open-label/Phase 2 Double-blind Placebo- Controlled Study for Pharmacodynamic (PD) Activity, Pharmacokinetics (PK), Safety, and Tolerability of KAN-101 In Patients With Celiac Disease (CeD)
- Lead sponsor
- Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- November 15, 2022
- Completion date
- May 19, 2025
- Enrollment
- 128 (actual)
- Sites
- 36
Conditions
As the registry lists them; a condition with its own page is linked.